UK FSA Regulatory Update Creates New Opportunity for CBD Brands to Reformulate with Pureis®

LONDON, UK [1 July 2025]: In a significant development for the UK Cannabidiol (CBD) industry, the Food Standards Agency (FSA) has issued new guidance setting a revised safe upper threshold of 0.07 mg THC per day for the average adult, raising compliance concerns for hemp-derived products; presenting opportunities for compliant products such as Pureis Ultra Pure CBD (CBDpur®); and accelerating the need for reformulated solutions.

This updated limit may render many hemp-derived CBD formulations non-compliant due to trace THC content, prompting the FSA to acknowledge that “some suppliers may no longer meet this specification.” The guidance also reaffirms the acceptable daily intake (ADI) for CBD at 10 mg – a threshold that aligns closely with most Pureis Ultra Pure CBD product formulations.

Pureis® Ultra Pure CBD: The Regulatory Gold Standard

In May 2024 Pureis® was the first synthetic CBD brand to achieve an endorsement from the FSA Scientific Committee with a Positive Safety Assessment, having invested significantly in safety clinical studies over the last decade. Pureis Ultra Pure CBD therefore remains fully compliant and unaffected by these new THC guidelines.

As the leading provider of synthetic CBD with non-detectable levels of THC, Pureis offers a proven and dependable solution with its Ultra Pure CBD product, thereby enabling brands to reformulate with confidence and certainty.

“We welcome the FSA’s guidance and the clarity it brings,” said Caroline Coen, Co-Founder and Chief Scientific Officer for Pureis, “It’s an important step toward safeguarding consumer trust and elevating product consistency. Pureis was built on the principles of safety, science, and regulatory foresight and we’re proud that our Ultra Pure CBD can offer an FSA compliant solution to brands navigating these changes.”